What does elutia (cormatrix) — gross carrying value mean?

This represents the total initial value of royalty-based financial assets associated with the Elutia and CorMatrix product lines before any valuation adjustments. It serves as a baseline measure of the company's investment or acquired rights in these specific medical technologies. Monitoring this value helps investors understand the scale of the underlying asset base prior to accounting for impairments or allowances.

Ligand Pharmaceuticals (LGND) Elutia (CorMatrix) — Gross carrying value

Screener

Other product segments

Qarziba

$101.3M—

Similar metrics at other companies

GNTXOther — Gross carrying value

$38.4M—

SIRISiriusXM — Gross Carrying Value

$8.61B0.0%

GLTexas — Carrying value, gross, percent

15%-2.0pp

GLFlorida — Carrying value, gross, percent

19%0.0pp

GLAlabama — Carrying value, gross, percent

8%-1.0pp

SIRISirius XM — Gross Carrying Value

$570M0.0%

Other financials

Income statement

See full

Revenue$63.7M+33.7%

Operating income$8.6M+1.7%

Net income$48.5M+901%

EPS (diluted)$2.22+825%

Balance sheet

See full

Cash & equivalents$1.0B+1,388%

Total debt$1.1B+19,605%

Total equity$967.5M+16.9%

Total assets$2.2B+130%

Cash flow

See full

Operating cash flow$24.0M+52.0%

CapEx$26.0K-87.9%

Free cash flow$24.0M+53.9%

Valuation

See full

Market cap$6.02B+119%

Enterprise value$6.14B+129%

P/E30.5×—

P/S20.7×+6.1×

Profitability

See full

Gross margin91.9%—

Operating margin32.6%+24.0pp

Net margin67.9%+49.4pp

FCF margin45.2%+16.7pp

Returns & leverage

See full

Return on equity22%+16.9pp

Debt / equity1.2×+1.2×

Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 4:06 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000886163-26-000044

Line item	June 30, 2026 / Gross carrying value(1)	June 30, 2026 / Allowance	June 30, 2026 / Net carrying value (1)	December 31, 2025 / Gross carrying value(1)	December 31, 2025 / Allowance	December 31, 2025 / Net carrying value(1)
Agenus Bot/Bal	40,815	(408)	40,407	40,815	(408)	40,407
Tolerance Therapeutics (Tzield®)	25,470	(99)	25,371	25,257	(98)	25,159
Ohtuvayre inventors	19,957	(179)	19,778	16,921	(151)	16,770
Elutia (CorMatrix)	6,062	(837)	5,225	6,607	(1,107)	5,500
AT220	4,442	(109)	4,333	5,132	(132)	5,000
Primrose mRNA	3,281	(98)	3,183	3,281	(98)	3,183
Zerion	2,640	(79)	2,561	—	—	—
Others	5,729	(212)	5,517	5,769	(214)	5,555

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's elutia (cormatrix) — gross carrying value?: Ligand Pharmaceuticals (LGND) reported elutia (cormatrix) — gross carrying value of $6.06M in Q2 2026.
What does elutia (cormatrix) — gross carrying value mean?: This represents the total initial value of royalty-based financial assets associated with the Elutia and CorMatrix product lines before any valuation adjustments. It serves as a baseline measure of the company's investment or acquired rights in these specific medical technologies. Monitoring this value helps investors understand the scale of the underlying asset base prior to accounting for impairments or allowances.